The overexpression of human epidermal growth factor receptor 2 (HER2) in patients with urothelial carcinoma (UC) is linked to more aggressive disease and poor outcomes, but the genetic basis of HER2 overexpression other than ERBB2 amplification in UC is not well understood. To resolve this knowledge gap, a research team led by Xiaolin Zhu, MD, PhD, retrospectively analyzed 172 tumor samples from 162 patients with upper tract and muscle invasive UC using immunohistochemistry (IHC) and next-generation sequencing. ...
Urothelial Carcinoma
Advertisement
Latest News
Researchers focused on the economic impact of disparities related to insurance coverage.
Researchers evaluated the data of 50 specimens from patients who underwent TURBT and cystectomy for UC.
Patients with localized UTUC have high unmet needs and tumors with a high frequency of FGFR3 alterations.
Drs. Gupta and Nizam discuss the findings from the patient-reported outcomes in the EV-302 trial for urothelial carcinoma.
The new recommendations included changes to neoadjuvant and adjuvant chemotherapy and radical cystectomy.
A recent dose-escalation study has demonstrated the safety and efficacy of cabo/nivo or cabo/nivo/ipi for several GU cancers.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
![PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC](https://mumcdnstorage.blob.core.windows.net/guonc/2024/06/122-GUOnc_YouTube_Sartor_1280x720.jpg)
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
Advertisement
Advertisement
Latest News
Researchers focused on the economic impact of disparities related to insurance coverage.
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
ACSS2 Inhibition as a Therapeutic Strategy in ccRCC: Impacts on HIF-2α, Metabolism, and Tumor Growth
The group discusses how blocking ACSS2 may affect immune cells in the tumor microenvironment. 